Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. New Engl J Med. 2011;364(6):535–41.
Article
CAS
PubMed
Google Scholar
Chatterjee SK, Rohrbaugh ML. NIH inventions translate into drugs and biologics with high public health impact. Nat Biotechnol. 2014;32:52.
Article
CAS
PubMed
Google Scholar
Weyerstahl T, Stauber M. Gynäkologie und Geburtshilfe. 3rd ed. Stuttgart: Georg Thieme Verlag; 2013.
Richens J, Mabey DCW. Sexually transmitted infections. In: Cook GC, Zumla AI, editors. Manson's tropical diseases. 22nd ed. Philadelphia: Saunders Elsevier; 2009. p. 403–35.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin. 2018;68(6):394–424.
Article
PubMed
Google Scholar
Oparka R, Herrington CS. Human papillomavirus infection and its association with Neoplasia: from molecular biology to prevention and treatment. In: Gaston K, editor. Small DNA Tumor Viruses. Poole: Caister Academic Press; 2012. p. 1–19.
Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, Denny LA. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa. Vaccine. 2013;31(Suppl 5):F47–52.
Article
PubMed
Google Scholar
McIntyre P. Finding the viral link: the story of Harald zur Hausen. Cancerworld. 2005; http://cancerworld.net/wp-content/uploads/2017/09/6737_cw7_32_37_Masterpiece-2.pdf. .
Grimes J. HPV vaccine development: A case study of prevention and politics. Biochem Mol Biol Edu. 2006;34(2):148–54.
Article
CAS
Google Scholar
Ghim S-J, Jenson AB, Schlegel R. HPV L1 protein expressed in cos cells displays conformational epitopes found on intact virions. J Virol. 1992;190(1):548–52.
Article
CAS
Google Scholar
Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992;89:12180–4.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL. Human papillomavirus type 11 recombinant capsomeres induce virus-neutralizing antibodies. J Virol. 1998;72(7):6151.
Article
CAS
PubMed
PubMed Central
Google Scholar
University of Rochester. http://www.urmc.rochester.edu/cancer-center/researchers/research-accomplishments/cervical-cancer-vaccine.aspx Accessed 2 Dec 2018.
Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995;92(25):11553–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schiller JT, Lowy DR. Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol. 1996;7(6):373–82.
Article
CAS
PubMed
Google Scholar
Crager S, Guillen E, Price M. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy. Am J Law Med. 2009;35.
Article
Google Scholar
Padmanabhan S, Amin T, Sampat B, Cook-Deegan R, Chandrasekharan S. Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India. Nat Biotech. 2010;28(7):671–8.
Article
CAS
Google Scholar
Clark A. Biomedical innovation and the politics of scientific knowledge: a case study of Gardasil. University of Maryland. 2008.
World Health Organization. 21th WHO Model List of Essential Medicines. 2019. https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf?ua=1. Accessed 10 Sept 2019.
International Covenant on Economic, Social and Cultural Rights, A/RES/2200A [XXI]. United Nations General Assembly; 1966. https://www.un.org/en/development/desa/population/migration/generalassembly/docs/globalcompact/A_RES_2200A(XXI)_civil.pdf. Accessed 9 Mar 2019.
United Nations Secretary-General's High-Level Panel on Access to Medicines Report. United Nations Secretary-General's High-Level Panel on Access to Medicines. 2016. http://www.unsgaccessmeds.org/final-report. Accessed 20 Apr 2018.
Progress towards the Sustainable Development Goals (E/2016/75). United Nations; 2016. https://www.un.org/ga/search/view_doc.asp?symbol=E/2016/75&Lang=E. Accessed 10 May 2019.
The Lancet's Commission on Essential Medicines Policies. Essential medicines for universal health coverage. Lancet. 2016;389(10067) https://doi.org/10.1016/S0140-6736(16)31599-9.
Article
Google Scholar
de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–15.
Article
PubMed
Google Scholar
Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global Burden of Human Papillomavirus and Related Diseases. Vaccine. 2012;30(Supplement 5):F12–23.
Article
PubMed
Google Scholar
Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453–e63.
Article
PubMed
Google Scholar
Gallagher KE, LaMontagne DS, Watson-Jones D. Status of HPV vaccine introduction and barriers to country uptake. Vaccine. 2018;36(32, Part A):4761–7.
Article
CAS
PubMed
Google Scholar
Hutubessy R, Levin A, Wang S, Morgan W, Ally M, John T, et al. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO cervical Cancer prevention and control costing tool. BMC Med. 2012;10:136.
Article
PubMed
PubMed Central
Google Scholar
Kaddar M, Schmitt S, Makinen M, Milstien J. Global support for new vaccine implementation in middle-income countries. Vaccine. 2013;31(Supplement 2):B81–96.
Article
PubMed
Google Scholar
Clendinen C, Zhang Y, Warburton RN, Light DW. Manufacturing costs of HPV vaccines for developing countries. Vaccine. 2016;34(48):5984–9.
Article
PubMed
Google Scholar
MSF AccessCampaign. A fair shot for vaccine affordability: understanding and addressing the effects f patents on access to newer vaccines. 2017. https://msfaccess.org/fair-shot-vaccine-affordability. .
Google Scholar
Herlihy N, Hutubessy R, Jit M. Current global pricing for human papillomavirus vaccines brings the greatest economic benefits to rich countries. Health Aff. 2016;35(2):227–34.
Article
Google Scholar
GlaxoSmithKline plc. Annu Rep. 2017:2018 https://www.gsk.com/media/4751/annual-report.pdf.
Access to medicines and vaccines: Report by the Director-General [A72/17]. World Health Organization; 2019. http://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_17-en.pdf?ua=1. Accessed 20 May 2019.
Godt C. Equitable Licensing & Global Access: Lizenzpolitik & Vertragsbausteine. 2nd ed. Bielefeld: BUKO Pharma-Kampagne; 2017.
Chen CE, Gilliland CT, Purcell J, Kishore SP. The silent epidemic of Exclusive University licensing policies on compounds for neglected diseases and beyond. PLoS Neglect Trop D. 2010;4(3):e570.
Article
Google Scholar
Guebert JM, Bubela T. Implementing Socially Responsible Licensing for Global Health: Beyond Neglected Diseases. Sci Transl Med. 2014;6(260):260cm11.
Article
PubMed
Google Scholar
Nelsen L. The role of university technology transfer operations in assuring access to medicines and vaccines in developing countries. Yale J Health Policy Law Ethics. 2013;3(]): 6.
Google Scholar
Yale University Center for Interdisciplinary Research on AIDS. Access to essential medicines and university research: building best practices. Yale University; 2003. http://cira.med.yale.edu/. Accessed 21 June 2017.
BUKO Pharmakampagne. Pharmabrief Spezial - Leitfaden für sozial-verträgliche Verwertung - Forschungsergebnisse für möglichst viele Menschen nutzbar machen. 2018. https://www.bukopharma.de/images/pharmabriefspezial/2018/PBS_2018-1_Leitfaden.pdf. .
Google Scholar
Etzkowitz H, Leydesdorff L. The dynamics of innovation: from National Systems and “mode 2” to a triple Helix of university–industry–government relations. Res Policy. 2000;29(2):109–23.
Article
Google Scholar
Ranga M, Etzkowitz H. Triple Helix systems: an analytical framework for innovation policy and practice in the knowledge society. Ind High Educ. 2013;27(4):237–62.
Article
Google Scholar
Bradley S, Hayter C, Link A. Models and methods of university technology transfer. UNCG economics working paper series 13-10. Greensboro: University of North Carolina; 2013.
Perkman M, Tartari V, McKelvey M, Autio E, Broström A, D’Este P. Academic engagement and commercialization: a review of the literature on university-industry relations. Res Policy. 2013;42:423–42.
Article
Google Scholar
Etzkowitz H. The norms of entrepreneurial science: cognitive effects of the new university–industry linkages. Res Policy. 1998;27(8):823–33.
Article
Google Scholar
Jahn R, Müller O, Bozorgmehr K. Characteristics and determinants of knowledge transfer policies at universities and public institutions in medical research—protocol for a systematic review of the qualitative research literature. Systematic Reviews. 2015;4(1):1–5.
Article
CAS
Google Scholar
Joanna Briggs Institute. Joanna Briggs Institute Reviewer’s Manual 2014. http://joannabriggs.org/assets/docs/sumari/ReviewersManual-2014.pdf. Accessed 14 Oct 2014.
Black N. Why we need qualitative research. J Epidemiol Commun H. 1994;48(5):425–6.
Article
CAS
Google Scholar
The Clinical Appraisal Skill Programme. Qualitative Research Checklist. http://www.caspinternational.org/mod_product/uploads/CASP%20Qualitative%20Research%20Checklist%2031.05.13.pdf. Accessed 14 Oct 2014.
Campbell R, Pound P, Morgan M, Daker-White G, Britten N, Pill R, et al. Evaluating meta-ethnography: systematic analysis and synthesis of qualitative research. Health Technol Assess. 2011;15(43):1–164.
Article
CAS
PubMed
Google Scholar
Erickson BK, Landers EE, Huh WK. Update on vaccination clinical trials for HPV-related disease. Clin Ther. 2014;36(1):8–16.
Article
PubMed
Google Scholar
Gersch ED, Gissmann L, Garcea RL. New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention. Antivir ther. 2012;17(3):425–34.
Article
CAS
PubMed
Google Scholar
Kanda T, Kondo K. Development of an HPV vaccine for a broad spectrum of high-risk types. Hum Vaccines. 2009;5(1):43–5.
Article
CAS
Google Scholar
Kondo K, Ochi H, Matsumoto T, Yoshikawa H, Kanda T. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J Med Virol. 2008;80(5):841–6.
Article
CAS
PubMed
Google Scholar
Cho H-J, Oh Y-K, Kim YB. Advances in human papilloma virus vaccines: a patent review. Expert Opin Ther Pat. 2011;21(3):295–309.
Article
CAS
PubMed
Google Scholar
Moscicki A-B. HPV Vaccines: Today and in the Future. J Adolesc Health. 2008;43(4, Supplement):S26–40.
Article
PubMed
PubMed Central
Google Scholar
Tyler M, Tumban E, Chackerian B. Second-generation prophylactic HPV vaccines: successes and challenges. Expert Rev Vaccines. 2014;13(2):247–55.
Article
CAS
PubMed
Google Scholar
Rybicki EP. Plant-produced vaccines: promise and reality. Drug Discov Today. 2009;14(1–2):16–24.
Article
CAS
PubMed
Google Scholar
Nieto K, Weghofer M, Sehr P, Ritter M, Sedlmeier S, Karanam B, et al. Development of AAVLP (HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One. 2012;7(6):e39741.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tumban E, Peabody J, Tyler M, Peabody DS, Chackerian B. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS One. 2012;7(11):e49751.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, et al. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol. 2013;133(12):2706–13.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jagu S, Kwak K, Karanam B, Huh WK, Damotharan V, Chivukula SV, et al. Optimization of Multimeric human papillomavirus L2 vaccines. PLoS One. 2013;8(1):e55538.
Article
CAS
PubMed
PubMed Central
Google Scholar
Buse K, Mays N, Walt G. Making health policy. 1st ed. Ottawa: Open University Press; 2012.
Google Scholar
Ritchie J, Spencer L. Qualitative data analysis for applied research. In: Huberman AM, Miles MB, editors. The qualitative researcher's companion. Thousand Oaks: SAGE Publications Inc; 2002. p. 305–29.
Ard CF. The commercialization of clinical genetic technologies: a technology assessment using fluorescence in situ hybridization as the genetic lens [dissertation]. Brandeis University. 2002.
Bacevice PA. Small world, big ideas, and smart companies–a qualitative study of academic spin-off companies and knowledge creation: University of Michigan; 2010.
Google Scholar
Owen-Smith J, Powell WW. Careers and contradictions: Faculty responses to the transformation of knowledge and its uses in the life sciences. in Steven Avvals, editor. The Transformation of Work (Research in the Sociology of Work, Vol 10). Emerald Group Publishing Limited, 2001. p.109–140..
Villasana M. Fostering university-industry interactions under a triple helix model: the case of Nuevo Leon. Mexico Sci Publ Policy. 2011;38(1):43–53.
Article
Google Scholar
Wadmann S. Physician–industry collaboration: conflicts of interest and the imputation of motive. Soc Stud Sci. 2014;44(4):531–54.
Article
PubMed
Google Scholar
Dooley L, Kirk D, Philpott K. Nurturing life-science knowledge discovery: managing multi-organisation networks. Prod Plan Control. 2013;24(2–3):195–207.
Article
Google Scholar
Filieri R, McNally RC, O'Dwyer M, O'Malley L. Structural social capital evolution and knowledge transfer: evidence from an Irish pharmaceutical network. Ind Mark Manag. 2014;43(3):429–40.
Article
Google Scholar
Lander B, Atkinson-Grosjean J. Translational science and the hidden research system in universities and academic hospitals: a case study. Soc Sci Med. 2011;72(4):537–44.
Article
PubMed
Google Scholar
Roback K. Medical device innovation: the integrated processes of invention, diffusion and deployment [dissertation]: Linköping University; 2006.
Colaianni A, Cook-Deegan R. Columbia University's Axel patents: technology transfer and implications for the Bayh-dole act. Milbank Q. 2009;87(3):683–715.
Article
PubMed
PubMed Central
Google Scholar
Styhre A. Coping with the financiers: attracting venture capital investors and end-users in the biomaterials industry. Technol Anal Strateg. 2014;26(7):797–809.
Article
Google Scholar
Shah R, Singer PA, Daar AS. Science-based health innovation in Tanzania: bednets and a base for invention. BMC int health human r. 2010;10(Suppl 1):S4.
Article
Google Scholar
Rowe S, Alexander N, Kretser A, Steele R, Kretsch M, Applebaum R, et al. Principles for building public-private partnerships to benefit food safety, nutrition, and health research. Nutr Rev. 2013;71(10):682–91.
Article
PubMed
Google Scholar
Valdivia WD. University start-ups: critical for improving technology transfer. Center for Technology Innovation at Brookings Washington, DC: Brookings Institution. 2013.
Cuntz A, Dauchert H, Meurer P, Philipps A, Platz P. Hochschulpatente zehn Jahre nach Abschaffung des Hochschullehrerprivilegs. Studien zum deutschen Innovationssystem Nr 13–2012. Berlin: Expertenkommission Forschung und Innovation; 2012. p. 13.
Google Scholar
Penin J. On the consequences of Patenting University research: lessons from a survey of French academic inventors. Ind Innov. 2010;17(5):445–68.
Article
Google Scholar
DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
Article
PubMed
Google Scholar
Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health policy. 2011;100(1):4–17.
Article
PubMed
Google Scholar
Hirschler B. GlaxoSmithKline boss says new drugs can be cheaper. Reuters. 2013; https://www.reuters.com/article/us-glaxosmithkline-prices/glaxosmithkline-boss-says-new-drugs-can-be-cheaper-idUSBRE92D0RM20130314. .
DNDi.Research & Development for Diseases of the Poor: A 10-Year Analysis of Impact of the DNDi Model [press release]. 2013. https://www.dndi.org/2013/media-centre/press-releases/dndi-rd-model/ Accessed 2 Dec 2018.
World Health Organization. Vaccine Market 2016 http://www.who.int/immunization/programmes_systems/procurement/market/global_demand/en/. Accessed 2 Dec 2018.
Plahte J. Tiered pricing of vaccines: a win-win-win situation, not a subsidy. Lancet Infect Dis. 2005;5(1):58–63.
Article
PubMed
Google Scholar
Rafols I, Hopkins MM, Hoekman J, Siepel J, O'Hare A, Perianes-Rodríguez A, et al. Big Pharma, little science?: a bibliometric perspective on big Pharma's R&D decline. Technol Forecast Soc. 2014;81:22–38.
Article
Google Scholar
AstraZeneca. AstraZeneca Annual Report 2010. London: AstraZeneca; 2010. https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2010-Annual-Report-English.pdf. .
Moses H III, Matheson DM, Cairns-Smith S, George BP, Palisch C, et al. The anatomy of medical research: US and international comparisons. JAMA. 2015;313(2):174–89.
Article
CAS
PubMed
Google Scholar
Kneller R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat Rev Drug Discov. 2010;9(11):867–82.
Article
CAS
PubMed
Google Scholar
Sampat BN, Lichtenberg FR. What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Affair. 2011;30(2):332–9.
Article
Google Scholar
Marston HD, Dixon DM, Knisely JM, Palmore TN, Fauci AS. Antimicrobial resistance. JAMA. 2016;316(11):1193–204.
Article
CAS
PubMed
Google Scholar
Lexchin J. Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications. Sci Eng Ethics. 2012;18(2):247–61.
Article
PubMed
Google Scholar
Littmann J, Viens AM. The ethical significance of antimicrobial resistance. Public Health Eth. 2015;8(3):209–24.
Google Scholar
World Health Organization. Research and Development to meet health needs in developing countries: strengthening global financing and coordination. Report of the consultative expert working group on research and development: financing and coordination. World Health Organization; 2012. https://www.who.int/phi/CEWG_Report_5_April_2012.pdf. Accessed 27 Apr 2019.
European Commission. Report from the Commission to the Council and the European Parliament: Competition Enforcement in the Pharmaceutical Sector, European competition authorities working together for affordable and innovative medicines. Luxembourg; 2019. https://ec.europa.eu/competition/publications/reports/kd0718081enn.pdf Accessed 10 Sept 2019.
Baker D, Jayadev A, Stiglitz J. Innovation, intellectual property, and development: A better set of approaches for the 21st century. 2017. http://cepr.net/images/stories/reports/baker-jayadev-stiglitz-innovation-ip-development-2017-07.pdf .
Google Scholar
Stiglitz JE, Jayadev A. Medicine for tomorrow: some alternative proposals to promote socially beneficial Research and Development in pharmaceuticals. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector. 2010;7(3):217–26.
Article
Google Scholar
Universities Allied For Essential Medicines. RE:ROUTE: A map of the alternative biomedical R&D landscape 2017. http://altreroute.com/. .
Google Scholar
Chokshi DA. Improving access to medicines in poor countries: the role of universities. PLoS med. 2006;3(6):e136–e.
Article
PubMed
PubMed Central
Google Scholar
The AUTM Global Health Toolkit: AUTM. https://autm.net/surveys-and-tools/tools/global-health-toolkit .Accessed 2 Dec 2018.
Universities Allied For Essential Medicines. University Report Card: Global Equity and Biomedical Research. http://globalhealthgrades.org/. Accessed 2 Dec 2018.